Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors.
Lechner K, von Schacky C, McKenzie AL, Worm N, Nixdorff U, Lechner B, Kränkel N, Halle M, Krauss RM, Scherr J.
Eur J Prev Cardiol. 2020 Mar;27(4):394-406. doi: 10.1177/2047487319869400. Epub 2019 Aug 13.
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies.
Rees MJ, D'Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520. doi: 10.1200/EDBK_433520.
Preoperative Pulmonary Risk Assessment.
Sameed M, Choi H, Auron M, Mireles-Cabodevila E.
Respir Care. 2021 Jul;66(7):1150-1166. doi: 10.4187/respcare.09154.
Lipoprotein(a) and cardiovascular disease.
Nordestgaard BG, Langsted A.
Lancet. 2024 Sep 28;404(10459):1255-1264. doi: 10.1016/S0140-6736(24)01308-4. Epub 2024 Sep 12.
Early Cerebral Palsy Detection and Intervention.
Mendoza-Sengco P, Lee Chicoine C, Vargus-Adams J.
Pediatr Clin North Am. 2023 Jun;70(3):385-398. doi: 10.1016/j.pcl.2023.01.014. Epub 2023 Mar 21.
Heaven can wait for lipid control in very high cardiovascular risk patients.
Mello E Silva A.
Rev Port Cardiol (Engl Ed). 2021 Sep;40(9):649-651. doi: 10.1016/j.repce.2021.08.005.
Plasma proteomic profiles predict individual future health risk.
You J, Guo Y, Zhang Y, Kang JJ, Wang LB, Feng JF, Cheng W, Yu JT.
Nat Commun. 2023 Nov 28;14(1):7817. doi: 10.1038/s41467-023-43575-7.
Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.
Ferraz-Amaro I, Corrales A, Quevedo-Abeledo JC, Vegas-Revenga N, Blanco R, Portilla V, Atienza-Mateo B, González-Gay MÁ.
Arthritis Res Ther. 2021 Jun 4;23(1):162. doi: 10.1186/s13075-021-02542-7.
Assessing Cardiovascular Risk in Patients with Diabetes: An Update.
Damaskos C, Garmpis N, Kollia P, Mitsiopoulos G, Barlampa D, Drosos A, Patsouras A, Gravvanis N, Antoniou V, Litos A, Diamantis E.
Curr Cardiol Rev. 2020;16(4):266-274. doi: 10.2174/1573403X15666191111123622.
Prognostic Significance of Hypertriglyceridemia in Patients at High and Very High Cardiovascular Risk Depending on the Concentration of Highsensitivity C-reactive Protein.
Genkel V, Kuznetsova A, Pykhova L, Nikushkina K, Savochkina A, Dolgushin I, Shaposhnik I.
Endocr Metab Immune Disord Drug Targets. 2022;22(14):1403-1409. doi: 10.2174/1871530322666220427094330.
